Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
Study First Submitted
Endpoints
Primary
Number of participants with Adverse Events(AEs)
Timeframe: up to to approximately 2.5 years since last participant in
Secondary (9)
Participants from EFC17919A, EFC17919B, and EFC17504 studies only: time to onset of 6-month composite confirmed disability worsening(cCDW) for RMS or composite confirmed disability progression(cCDP) for nrSPMS
Time to onset of individual components of the composite, confirmed over 3 months or 6 months EDSS for all prior study participants 9-HPT, T25FW test (participants rolling over from EFC17504, EFC17919A, and EFC17919B)
Progression independent of relapse activity defined as the time to onset of 6-month cCDW
Number of new and/or enlarging T2-hyperintense lesions per year as detected by MRI
Total number of new GdE T1 lesions per year as detected by MRI
Show 4 moreShow less
Change from baseline at scheduled visits in total volume of T2-hyperintense lesions as detected by brain MRI
ARR assessed by confirmed protocol defined relapses
antidrug antibodys(ADAs) incidence
Change from baseline in serum immunoglobulin(Ig) levels
Arms and interventions
Frexalimab SC (OL)Experimental
Participants will be administered frexalimab subcutaneous
Frexalimab IV (OL)Experimental
Participants will be administered frexalimab intravenously
Frexalimab (DB)Experimental
For EFC17919A/B parent study participants: at Opt-in visit participants will continue to be administered f rexalimab through unblinding visit. Participants will receive placebo tablet once daily until the unblinding visit.
Teriflunomide (DB)Active comparator
For EFC17919A/B parent study participants: at Opt-in visit participants will continue to receive teriflunomide tablet. The placebo will be administered to participants at the same infusion rate and duration as for frexalimab from the opt-in visit until availability of results and unblinding.